Page 28 - Cll News Today

Florida Cancer Specialists recently released a case study that outlined its role in the evolution of a first-line therapy for adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) that recently received FDA approval.

1. High genetic risk participants with chronic lymphocytic leukemia (CLL) taking venetoclax in addition to ibrutinib achieved high rates of achievement of undetectable measurable disease, very low risk of on-treatment disease progression, and durable off-treatment remissions. Evidence Rating Level: 2 (Good) Ibrutinib is an inhibitor of Bruton’s tyrosine kinase (BTK), and one of its indicated

Findings from a study demonstrated that patients may develop hypertension, or high blood pressure, as a result of treatment with Imbruvica for CLL, although it may be quickly managed without drug-drug interactions.

Lori A. Leslie, MD, and Hoshiyuki Iida, APN, offer closing thoughts on the future treatment landscape of chronic lymphocytic leukemia.

Yiming Wu, PhD, discusses a study identifying METTL3-mediated N6-methyladenosine modification as a key translational regulator of splicing factors, and how this mechanism contributes to the progression of chronic lymphocytic leukemia.

Insights on supportive care and approaches to managing adverse effects of BTK inhibitors in the treatment of chronic lymphocytic leukemia.

Experts on chronic lymphocytic leukemia discuss how to approach cost considerations and available resources for CLL treatments.

MyJournals.org - Science - Energies, Vol. 16, Pages 3637: 3D Transient CFD Simulation of an In-Vessel Loss-of-Coolant Accident in the EU DEMO WCLL Breeding Blanket (Energies)

An ultrasound revealed a solid mass in my breast that would need further follow-up.

Lori A. Leslie, MD, an expert on CLL, talks about factors that influence treatment decisions.